CSF1 and central nervous system cancer: Regarding CSF-1R/CSF-1 axis as a target for therapy, we have demonstrated that CSF-1R inhibition by PLX3397 affected more M2 than M1 macrophages, and induces their repolarization towards an M1-like phenotype, in accord with published results in glioma [56, 57].